Our ImmunoTherapies

The MVI approach to immunotherapy development

Our current vaccine therapies

MVI is committed to exploring use of our plasmids in combinations across the prostate cancer disease spectrum.

We have run trials in early stage non-metastatic prostate cancer, during early therapy for metastatic prostate cancer, and during the later stages of castration-resistant metastatic prostate cancer.